Delivery Order SPE2DB25D9348-SPE2DB26FNMNH
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,373.61 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nuplazid 10 mg tablets (30-count packages). The award, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries a firm fixed-price contract type with no set-aside designation, indicating the vendor competed in unrestricted federal...
- The Defense Logistics Agency awarded a delivery order valued at $10,588.89 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count packages). The award, issued on October 28, 2025, with an ultimate completion date of November 19, 2025, utilizes firm fixed-price pricing and does not include a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on October 30, 2025, for Nuplazid 34 mg capsules (30-count packaging) valued at $10,375.53. This firm fixed-price delivery order, which carries no set-aside designation, represents a specific fulfillment under the company's broader Indefinite Delivery Contract with DLA. The contract will be completed by November...
- The Defense Logistics Agency awarded a delivery order valued at $20,751.06 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of NUPLAZID 34 mg capsules (30-count packaging). This firm fixed-price delivery order, issued on October 23, 2025, with an ultimate completion date of November 14, 2025, carries no set-aside designation, indicating the award was made through open competition. The delivery order was...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $3,458.51 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Nuplazid 34 mg capsules and has a performance period through May 12, 2025. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) worth up to $499,999,999 with the DLA under the SPE2DB program, which enables the agency to issue delivery orders...
- The Defense Logistics Agency awarded a $21,177.78 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules in quantities of 30. The delivery order, issued on October 31, 2025, with an ultimate completion date of November 24, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group was...
- The Defense Logistics Agency issued a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules in 30-count packaging. This delivery order was awarded on September 8, 2025, with an ultimate completion date of September 29, 2025, utilizing firm fixed-price pricing with no set-aside designation. The order represents a discrete fulfillment under DMS...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count units) with a ceiling value of $3,458.51. The contract was awarded on September 9, 2025, with an ultimate completion date of September 30, 2025, utilizing firm fixed-price pricing with no set-aside designation. This delivery order is issued under DMS Pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules in 30-count units. The award, issued on July 21, 2025, with an ultimate completion date of August 11, 2025, carries a firm fixed-price contract structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- The Defense Logistics Agency awarded a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units), with an ultimate completion date of October 6, 2025. This firm fixed-price delivery order, issued on September 15, 2025, carries no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform this work at its primary facility in...
- SPE2DB25D9348Indefinite Delivery Contract
- SPE2DB25D9348-SPE2DB26FNMNHDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count). This firm fixed-price delivery order, issued on November 4, 2025, with an ultimate completion date of November 26, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded on November 13, 2025. DMS Pharmaceutical Group holds a $499.999 billion ceiling IDC under the broader $30.3 billion PPV-G GEN V acquisition strategy, positioning the company as a critical regional prime vendor contractor for the Department of Defense's pharmaceutical supply chain. The underlying contract authorizes DLA to issue delivery orders for a comprehensive range of pharmaceuticals—including branded and generic prescription drugs, biologics, and medical consumables—to support military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance on numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of federal military medical operations globally, with a contract term extending through December 31, 2036, encompassing a 30-month base period and three 30-month option periods.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 11/4/25 |